Chronic Total Occlusion: Bioresorbable Scaffolds or Drug Eluting Stents?

Chronic Total Occlusion: Bioresorbable Scaffolds or Drug Eluting Stents?

There is little evidence to support the safety and efficacy of bioresorbable scaffolds (BRS) for the treatment of chronic total occlusions (CTO).

 

This multicenter registry included consecutive patients with CTO receiving BRS (Absorb; Abbott Vascular) vs. 2nd generation drug eluting stents (DES).

 

Primary end point was target vessel failure at long term (composite of cardiac death, target vessel myocardial infarction, and ischemia driven target lesion revascularization). Logistic regression was used to adjust for differences between the groups.

 

A total of 537 patients (n=153 BVS; n=384 DES) were included. Patients receiving BRS resulted younger and had less comorbidities.

 

Mean J-CTO score (Japan-Chronic Total Occlusion) was 1.43±1.16 and resulted similar between the groups.

 

The procedure was successful in 99.3% of cases treated with BRS and in 96.6% of cases treated with DES (p=0.07).

 

At mean 703 days there were no differences between the two groups as regards primary end point (4.6% vs 7.7%; p=0.21). Nor were there any differences after adjusted analyzis. However, a secondary analyzis suggest a tendency towards higher ischemia driven TVR rate for the BRS group.

 

Conclusion

The use of bioresorbable scaffolds compared to 2nd generation DES in CTO showed a similar rate of target vessel failure at long term. However, there was a tendency towards more ischemia driven target lesion revascularization. These findings should be confirmed by randomized studies.

 

Original Title: Procedural and Long-Term Outcomes of Bioresorbable Scaffolds versus Drug-Eluting Stents in Chronic Total Occlusions. The BONITO Registry (Bioresorbable Scaffolds versus Drug-Eluting Stents in Chronic Total Occlusions).

Reference: Lorenzo Azzalini et al. Circulation: Cardiovascular Interventions. 2016; 9. Epub ahead of print.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....